Brief: Enanta Pharmaceuticals Announces Positive Data From A Phase 1 Clinical Study Of EDP-323, An Oral, L-Protein Inhibitor In Development For Treatment Of RSV

Enanta Pharmaceuticals

20/06/2023 12:16

June 20 (Reuters) - Enanta Pharmaceuticals Inc  ENTA.O :
    * ENANTA PHARMACEUTICALS INC: POSITIVE DATA FROM A PHASE 1
CLINICAL STUDY OF EDP-323, AN ORAL, L-PROTEIN INHIBITOR IN
DEVELOPMENT FOR TREATMENT OF RSV
    * ENANTA PHARMACEUTICALS: EDP-323 GENERALLY SAFE AND
WELL-TOLERATED UP TO 800 MG FOR SEVEN DAYS WITH PHARMACOKINETICS
SUPPORTIVE OF ONCE-DAILY DOSING
    * ENANTA PHARMACEUTICALS INC: ALL DOSES RESULTED IN STRONG
EXPOSURE MULTIPLES AGAINST BOTH RSV A AND B STRAINS IN STUDY
    * ENANTA PHARMACEUTICALS INC: HUMAN CHALLENGE STUDY TO BE
INITIATED BY EARLY Q4 2023

Source text for Eikon:  ID:nBw4VjxZba 
Further company coverage:  ENTA.O 

 ((reuters.briefs@thomsonreuters.com;))